Tvs Motor Company, an Indian based global two-wheeler and three-wheeler manufacturer and the flagship company of the USD 8.5 billion TVS Group, has agreed on a long-term strategic a partnership with Ego Movement, a fast-growing Swiss
Search Results for: vischer
Anjarium Biosciences, a Swiss biotech company, recently closed a CHF 55.5 million (USD 61 million) Series A financing round, co-led by Gimv and Abingworth. The fundraising also saw significant participation from Omega Funds, Pfizer Ventures and surveyor
The shareholders of S.R.I.F. NV, the parent company of the Asco Group, and the Swiss listed Montana Aerospace group, a highly-vertically integrated manufacturer and supplier of system components and complex assemblies for
Novaremed, a privately held clinical-stage biopharmaceutical company, expands its pipeline of non-opioid treatment candidates for chronic pain indications through the acquisition of Metys Pharmaceuticals. The acquisition broadens Novaremed’s existing pipeline by adding both
EnBiotix, a Boston-based biotech company focused on rare diseases, is merging with Swiss oncology and antimicrobial resistance-focused company Polyphor. A merger agreement under which Polyphor will use all of EnBiotix’s outstanding share capital in
Combioxin, a clinical phase biotechnology company based in Epalinges, Switzerland, has signed a worldwide commercial license agreement with Eagle Pharmaceuticals, a fully integrated pharmaceutical company based in Woodcliff Lake, NY, USA. Under the terms of
La Mobilière, TX Group, Ringier and General Atlantic form a joint venture to create a digital marketplace group. The CEO of the joint venture will be Gilles Despas, currently CEO of the Scout24 Switzerland
Vischer announced the addition of Karin Graf (pictured) to the firm’s litigation and arbitration team, in the role of partner. Graf assumes her new role as of September 1st. Graf brings with her more
Vischer’s dispute resolution team successfully represented a Swiss bank in a multi-faceted conflict, defending against allegations of corruption and breaches of contract as well as massive claims for damages. The dispute included commercial court
Biopharmaceutical company Relief Theraputics Holding, has a binding agreement with two institutional U.S. investors completed. The contract provides for the purchase of Relief shares with a total value of CHF 15 million, which come from